[{"id":"7bc669f9-70e9-4c55-a53a-75abe050ae78","acronym":"","url":"https://clinicaltrials.gov/study/NCT02042430","created_at":"2021-01-18T09:22:47.961Z","updated_at":"2024-07-02T16:35:15.364Z","phase":"Phase 1","brief_title":"Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02042430","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDO1","pipe":" | ","alterations":" IDO1 expression","tags":["IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 03/31/2016","primary_completion_date":" 03/31/2016","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"5ee1ae6e-0047-4793-9812-f63a9637ae81","acronym":"","url":"https://clinicaltrials.gov/study/NCT03089606","created_at":"2021-01-18T15:13:27.812Z","updated_at":"2024-07-02T16:35:29.135Z","phase":"Phase 2","brief_title":"Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker","source_id_and_acronym":"NCT03089606","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" LAG3 • HAVCR2 • CD27","pipe":" | ","alterations":" IDO1 expression","tags":["LAG3 • HAVCR2 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 04/19/2017","start_date":" 04/19/2017","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2023-11-15"},{"id":"28520e3b-b67e-4eaa-88df-4b31a3271f54","acronym":"KEYNOTE-434","url":"https://clinicaltrials.gov/study/NCT02862457","created_at":"2021-01-18T14:03:08.705Z","updated_at":"2024-07-02T16:36:05.171Z","phase":"Phase 1","brief_title":"Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)","source_id_and_acronym":"NCT02862457 - KEYNOTE-434","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • PD-L1 • ALK • IDO1","pipe":" | ","alterations":" IDO1 expression","tags":["EGFR • PD-L1 • ALK • IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2022-08-19"},{"id":"6d4ff3f4-1d80-440a-9e46-70e91aa31170","acronym":"CELEBRIDO","url":"https://clinicaltrials.gov/study/NCT03896113","created_at":"2021-01-18T19:11:21.793Z","updated_at":"2024-07-02T16:36:51.476Z","phase":"Phase 2","brief_title":"Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma","source_id_and_acronym":"NCT03896113 - CELEBRIDO","lead_sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","biomarkers":" CD8 • IDO1 • CD4","pipe":" | ","alterations":" IDO1 expression","tags":["CD8 • IDO1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Unknown status","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2020-01-10"},{"id":"1805ea50-70a8-4f38-a983-2031dc6b40df","acronym":"NICE-COMBO","url":"https://clinicaltrials.gov/study/NCT03864575","created_at":"2021-01-18T19:03:48.254Z","updated_at":"2024-07-02T16:36:58.189Z","phase":"Phase 2","brief_title":"An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced \" Cold \" Solid Tumors","source_id_and_acronym":"NCT03864575 - NICE-COMBO","lead_sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","biomarkers":" BRAF • IDO1","pipe":" | ","alterations":" BRAF mutation • IDO1 expression • IDO1 positive","tags":["BRAF • IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • IDO1 expression • IDO1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • celecoxib oral"],"overall_status":"Unknown status","enrollment":" Enrollment 68","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2019-07-12"},{"id":"243ba471-ed4f-4827-a927-eef176ee41a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01961115","created_at":"2021-03-25T17:09:12.570Z","updated_at":"2024-07-02T16:37:10.185Z","phase":"Phase 2","brief_title":"Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT01961115","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" BRAF • CD8 • IFNG • CTLA4 • IDO1 • CD4","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • CD8 expression • IDO1 expression","tags":["BRAF • CD8 • IFNG • CTLA4 • IDO1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • CD8 expression • IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/13/2013","start_date":" 09/13/2013","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 05/18/2017","study_completion_date":" 05/18/2017","last_update_posted":"2018-06-08"},{"id":"61a00998-157a-41cf-9943-a69efc210996","acronym":"","url":"https://clinicaltrials.gov/study/NCT02736123","created_at":"2021-01-18T13:23:58.560Z","updated_at":"2024-07-02T16:37:17.684Z","phase":"Phase 1/2","brief_title":"Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone","source_id_and_acronym":"NCT02736123","lead_sponsor":"University of Pittsburgh","biomarkers":" PD-L1 • CD8 • IDO1","pipe":" | ","alterations":" PD-L1 expression • IDO1 expression","tags":["PD-L1 • CD8 • IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 02/09/2017","primary_completion_date":" 02/09/2017","study_txt":" Completion: 02/09/2017","study_completion_date":" 02/09/2017","last_update_posted":"2017-09-20"},{"id":"898eb250-6017-4c92-89d0-8578496c6ff8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02406183","created_at":"2021-01-18T11:29:20.301Z","updated_at":"2024-07-02T16:37:26.634Z","phase":"Phase 1","brief_title":"Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma","source_id_and_acronym":"NCT02406183","lead_sponsor":"Radiotherapie","biomarkers":" IDO1 • FOXP3","pipe":" | ","alterations":" IDO1 expression","tags":["IDO1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2017-01-10"}]